Verinata Health, Inc., a San Carlos, CA-based developer of a non-invasive prenatal diagnostic test, has closed an approximately $46.5m Series C financing.
A remaining portion of $2.0m is expected to close on August 31, 2011.
Investors include existing backers Mohr Davidow Ventures, Sutter Hill Ventures, and Alloy Ventures.
The company intends to use the funds to continue its research and development activities and subsequent commercialization of its test.
Led by CEO Caren L. Mason, Verinata Health is focusing on developing and commercializing non-invasive tests for early identification of fetal chromosomal abnormalities. The company is currently conducting a prospective, blinded pivotal study to clinically validate the sensitivity and specificity of its test on a large scale with results expected in 2011.